Soleno Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the SLNO Class Action

Core Viewpoint - A class action has been filed against Soleno Therapeutics for allegedly misleading investors regarding the safety and efficacy of its drug DCCR during its Phase 3 clinical trial [1][2]. Group 1: Allegations and Concerns - The complaint alleges that Soleno failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in trial participants [2]. - It is claimed that the administration of DCCR posed greater safety risks than disclosed, leading to materially lower commercial viability and undisclosed risks of adverse events post-launch [2]. - The allegations include that the company misrepresented the likelihood of patient discontinuation, lower adoption rates, and potential regulatory and reputational fallout [2]. Group 2: Impact on Stock Price - Following the release of a report by Scorpion Capital on August 15, 2025, which detailed issues with Soleno's clinical trial and safety concerns, the stock price fell nearly 12% over two trading days [3]. - After a patient death linked to DCCR was disclosed in a Form 8-K on September 10, 2025, the stock experienced a nearly 19% decline over two trading days [4]. - On November 4, 2025, after reporting third-quarter financial results, Soleno's stock dropped approximately 27% in one day, from nearly $64 to about $47 per share, attributed to concerns raised by the Scorpion Capital report [5].